Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.

摘要: Therapeutic agents that inhibit a single target often cannot combat multifactorial disease such as cancer. Thus, multi-target inhibitors (MTIs) are needed to circumvent complications the development of resistance. There two predominant types MTIs, (a) drug inhibitor (SDIs) affect multiple pathways simultaneously, and (b) combinatorial or multi-drug (MDIs) pathways. Single agent kinase amongst most prominent class compounds belonging former, whereas latter includes many different classes have been used achieve synergistic efficacy against Safe delivery accumulation at tumor site is paramount importance for MTIs because inhibition key signaling has potential lead systemic toxicity. For this reason, mechanisms using nanotechnology preferable in order ensure MDIs accumulate tumor vasculature, thereby increasing minimizing off-target side effects. This review will discuss how can be cancer therapy with focus on various nanoparticle formulations. It concludes discussion future nanoparticle-based well continuing obstacles being faced during these unique agents.